Cogent Biosciences, Inc.
NASDAQ•COGT
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2018-03-29
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
Contact Information
Market Cap
$6.31B
P/E (TTM)
-8.0
19.5
Dividend Yield
--
52W High
$43.73
52W Low
$3.72
52W Range
Rank47Top 61.9%
3.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q4 2025 Data
Revenue
$0.00+0.00%
4-Quarter Trend
EPS
-$0.69+0.00%
4-Quarter Trend
FCF
-$79.92M+0.00%
4-Quarter Trend
2025 Annual Earnings Highlights
Key Highlights
Bezuclastinib Clinical Progress Positive top-line results achieved for SM and GIST indications in 2025; NDA submission for NonAdvSM completed.
Financing Activities Strong Financing provided $878.2M in 2025, including $222.8M from Notes issuance, bolstering capital resources.
Cash Position Strong Cash, equivalents, and securities totaled $900.8M as of December 31, 2025, funding operations into 2028.
R&D Spending Increased Research and development expenses rose $37.1M to $269.78M in 2025, supporting clinical trial progression.
Risk Factors
Continued Net Losses Incurred Net loss reached $328.94M in 2025, increasing $73.08M from 2024; operations remain unprofitable.
Pipeline Dependency Risk Business success highly dependent on bezuclastinib program success; pipeline expansion requires substantial funding.
Manufacturing Sole Source Risk API and drug product for bezuclastinib rely on single-source suppliers; loss significantly harms business operations.
Regulatory Approval Uncertainty Regulatory plans may face disagreement from FDA; approval for all indications is not guaranteed.
Outlook
Commercial Launch Planned Expect US commercial launch for NonAdvSM in second half of 2026, pending successful FDA regulatory approval.
Pipeline Advancement Continues Plan to initiate Phase 1 study for ErbB2 inhibitor and submit IND for KRAS/JAK2 programs in 2026.
Future Capital Requirements Expect substantial future expenses; additional financing required to complete development and commercialization efforts.
GIST NDA Submission Target Expect to complete GIST NDA submission in April 2026, following RTOR acceptance in January 2026.
Peer Comparison
Revenue (TTM)
$2.20B
$1.26B
$247.00M
Gross Margin (Latest Quarter)
96.9%
94.2%
90.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| IBRX | $10.28B | -29.4 | 64.3% | 175.0% |
| COGT | $6.31B | -8.0 | -100.2% | 27.0% |
| DNLI | $3.28B | -7.2 | -50.1% | 2.9% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Deep Research
Next earnings:May 4, 2026
EPS:-
|Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data